AU2273701A - Hla class i a2 tumor associated antigen peptides and vaccine compositions - Google Patents
Hla class i a2 tumor associated antigen peptides and vaccine compositionsInfo
- Publication number
- AU2273701A AU2273701A AU22737/01A AU2273701A AU2273701A AU 2273701 A AU2273701 A AU 2273701A AU 22737/01 A AU22737/01 A AU 22737/01A AU 2273701 A AU2273701 A AU 2273701A AU 2273701 A AU2273701 A AU 2273701A
- Authority
- AU
- Australia
- Prior art keywords
- associated antigen
- hla class
- tumor associated
- vaccine compositions
- antigen peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17044899P | 1999-12-13 | 1999-12-13 | |
US60170448 | 1999-12-13 | ||
US09543608 | 2000-04-05 | ||
US09/543,608 US6602510B1 (en) | 2000-04-05 | 2000-04-05 | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
US58320000A | 2000-05-30 | 2000-05-30 | |
US09583200 | 2000-05-30 | ||
PCT/US2000/034318 WO2001041741A1 (fr) | 1999-12-13 | 2000-12-13 | Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2273701A true AU2273701A (en) | 2001-06-18 |
Family
ID=27389823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU22737/01A Abandoned AU2273701A (en) | 1999-12-13 | 2000-12-13 | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1242049A4 (fr) |
JP (1) | JP2003516344A (fr) |
AU (1) | AU2273701A (fr) |
CA (1) | CA2393730A1 (fr) |
WO (1) | WO2001041741A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1343819A4 (fr) * | 2000-09-01 | 2005-03-23 | Epimmune Inc | Peptides de fixation de hla-a2.1 et leurs utilisations |
EP1903056A3 (fr) * | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant |
US20060094649A1 (en) * | 2002-12-10 | 2006-05-04 | Keogh Elissa A | Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions |
MXPA05006113A (es) * | 2002-12-11 | 2005-09-30 | Pharmexa As | Epitopos sencillos objetivo. |
US20080274129A1 (en) * | 2003-04-18 | 2008-11-06 | Fikes John D | Hla-A2 Tumor Associated Antigen Peptides and Compositions |
EP1676132B1 (fr) | 2003-10-21 | 2014-01-22 | Cedars-Sinai Medical Center | La combinaison de la chimiothérapie et de l'administration de cellules dendritiques pulsée avev gliome antigènes dans le traitement du gliome |
WO2008039874A2 (fr) | 2006-09-26 | 2008-04-03 | Cedars-Sinai Medical Center | Vaccins comprenant des antigènes de cellules souches cancéreuses et procédés |
WO2008039969A2 (fr) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Vaccins contre le cancer et méthodes de vaccination |
WO2009059011A2 (fr) * | 2007-11-01 | 2009-05-07 | Mayo Foundation For Medical Education And Research | Peptides de liaison hla-dr et leurs utilisations |
EP2328923B1 (fr) | 2008-09-02 | 2016-01-13 | Cedars-Sinai Medical Center | Épitopes cd133 |
JP5792630B2 (ja) * | 2009-01-28 | 2015-10-14 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
US9764012B2 (en) * | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
WO2010129895A2 (fr) | 2009-05-07 | 2010-11-11 | Immunocellular Therapeutics, Ltd. | Epitopes des cd133 |
US10076491B2 (en) | 2013-02-05 | 2018-09-18 | Nitto Denko Corporation | Vaccine composition |
JP2014169280A (ja) * | 2013-02-05 | 2014-09-18 | Nitto Denko Corp | 経皮または粘膜投与用ワクチン組成物 |
WO2014127296A1 (fr) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Vaccins contre le cancer et méthodes de vaccination |
RU2627175C2 (ru) * | 2013-03-08 | 2017-08-03 | Тайхо Фармасьютикал Ко., Лтд. | Новый пептид, имеющий 5 соединенных эпитопов ctl |
EP3028048B1 (fr) | 2013-07-31 | 2018-09-26 | BioVentures, LLC | Compositions permettant de traiter et de prévenir le cancer par ciblage des antigènes glucidiques associés à la tumeur |
TWI651094B (zh) | 2013-10-21 | 2019-02-21 | 日商大鵬藥品工業股份有限公司 | 新穎ctl抗原決定部位4連結肽 |
GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
SG10202111399YA (en) | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
KR102663596B1 (ko) | 2017-04-26 | 2024-05-10 | 유레카 쎄라퓨틱스, 인코포레이티드 | 글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69435292D1 (de) * | 1993-03-05 | 2010-06-17 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden |
EP1012238A4 (fr) * | 1997-01-31 | 2003-03-05 | Epimmune Inc | Cellules a peptides ou a antigenes charges de peptides |
-
2000
- 2000-12-13 WO PCT/US2000/034318 patent/WO2001041741A1/fr active Application Filing
- 2000-12-13 EP EP00986510A patent/EP1242049A4/fr not_active Withdrawn
- 2000-12-13 CA CA002393730A patent/CA2393730A1/fr not_active Abandoned
- 2000-12-13 AU AU22737/01A patent/AU2273701A/en not_active Abandoned
- 2000-12-13 JP JP2001542909A patent/JP2003516344A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1242049A1 (fr) | 2002-09-25 |
WO2001041741A1 (fr) | 2001-06-14 |
JP2003516344A (ja) | 2003-05-13 |
WO2001041741A9 (fr) | 2002-05-30 |
EP1242049A4 (fr) | 2005-01-05 |
CA2393730A1 (fr) | 2001-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2273701A (en) | Hla class i a2 tumor associated antigen peptides and vaccine compositions | |
SI1620456T1 (sl) | Hla-a2 s tumorjem povezan antigen peptidov in sestavki | |
AU7912100A (en) | Pharmaceutical composition comprising an antigen | |
LU91326I2 (fr) | Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé) | |
AU2001255196A1 (en) | Compositions and methods for enhancing immunogenicity of antigens | |
SI1150712T1 (sl) | Pripravek cepiva proti humanem papiloma virusu | |
NL300415I1 (nl) | Vaccin tegen antigenen van bacteriën | |
AU2001252458A1 (en) | Molecular antigen arrays and vaccines | |
IL148456A0 (en) | Combined vaccine compositions | |
AU1951201A (en) | Peptide antigens | |
IL148247A (en) | Vaccine and its uses | |
AU2003262094A1 (en) | Cancer antigen peptide preparation | |
AU2001290860A1 (en) | Spas-1 cancer antigen | |
AU2001271976A1 (en) | Microspheres and adjuvants for dna vaccine delivery | |
AU1940301A (en) | Tick antigens and compositions and methods comprising them | |
AU7123500A (en) | Polysialic acid-klh conjugate vaccine | |
AU2977500A (en) | Advanced antigen presentation platform | |
AU2002243314A1 (en) | Immunogenic cancer peptides and uses thereof | |
AU7308200A (en) | Novel hev antigenic peptide and methods | |
HUP0202770A3 (en) | Human papilloma virus vaccine | |
AU2913400A (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
AUPQ257199A0 (en) | Vaccine antigens of moraxella | |
AU4957800A (en) | Vaccine against isa virus | |
AU5632500A (en) | Cancer associated antigens and uses therefor | |
AU2002340850A1 (en) | Antigen mimotopes and vaccine against cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |